超声引导下尾神经射频消融联合类固醇注射:尾骨痛联合治疗
前瞻性研究纳入32例保守治疗无效的尾骨痛患者,行超声引导下尾神经射频消融(90°C、60秒)联合地塞米松与布比卡因注射;治疗后1、4、12周视觉模拟量表(VAS)与Paris评分均显著改善(P<.001),54%患者VAS评分改善>50%,66%患者Paris评分改善>50%。
要点
- 超声在尾骨角水平可显示尾神经,作为射频消融与注射的靶点定位标志。
- 射频消融参数为90°C持续60秒,消融后注射地塞米松2 mL与0.5%布比卡因2 mL。
- 治疗后1、4、12周VAS与Paris评分较基线均显著下降(P<.001)。
核心结论
- 超声引导下尾神经类固醇注射联合射频消融可显著改善慢性尾骨痛患者第1、4、12周的疼痛与功能评分,且射频消融不良事件发生率较低。
研究设计与样本
- 前瞻性研究,纳入32例保守治疗无效的尾骨痛患者,行超声引导下尾神经射频消融联合注射治疗,以VAS和Paris评分于治疗前及治疗后1、4、12周评估。
关键影像表现/征象
- 超声在尾骨角水平可显示尾神经,作为穿刺与消融的定位标志。
- 于双侧尾神经区域各注射2%利多卡因1 mL后行射频消融,温度90°C、时间60秒。
- 射频消融后注射地塞米松2 mL与0.5%布比卡因2 mL。
诊断标准与关键数值
- 54%的患者在基线至第12周间VAS评分改善>50%。
- 66%的患者在基线至第12周间Paris评分改善>50%。
- 时间对VAS和Paris评分的主效应在所有测量中均有统计学意义(P<.001),基线Paris评分和VAS评分高于治疗后测量值(P<.001)。
临床应用与阅片要点
- 作者认为这种新的微创方法可能成为其他介入治疗的替代选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Coccydynia is characterized by pain in tailbone region, which affects the quality of life. Various interventional procedures are performed for coccydynia that is unresponsive to conservative treatment. This study aimed to evaluate the efficacy of ultrasound (US)-guided radiofrequency ablation (RFA) and steroid injection of the coccygeal nerve in patients with idiopathic and traumatic coccydynia.
METHODS: In this prospective study, 32 patients with coccydynia unresponsive to conservative treatments underwent US-guided RFA of the coccygeal nerve. Coccygeal nerves were visualized at the level of the coccygeal cornua with US, 1 mL lidocaine 2% was injected into both areas and radiofrequency ablation was performed at 90°C for 60 seconds. After RFA, 2 mL dexamethasone and 2 mL bupivacaine 0.5% were injected. Visual Analog Scale (VAS) and Paris scales were used to evaluate the effect of treatment on pain and functionality before and at 1, 4, and 12 weeks after treatment.
RESULTS: We found that 54% of the patients had a >50% reduction in VAS score and 66% of the patients had a >50% reduction in Paris scores measured between baseline and week 12. Additionally, the main effect of time on the VAS and Paris scores was statistically significant (P < .001) in all measurements. Baseline P and VAS scores were higher than the post-treatment measurements (P < .001).
CONCLUSIONS: Our study showed that US-guided steroid injection and RFA of the coccygeal nerve for chronic coccydynia significantly improved pain and function scores at weeks 1, 4, and 12. RFA also results in a lower rate of adverse events. This study is the first clinical trial of ultrasound-guided coccygeal nerve RFA in patients with coccydynia. We believe that this new less invasive method may be an alternative to other interventional treatments.
引用
- Can E, Yildiz G, Akkaya ÖT, et al. Ultrasound-Guided Coccygeal Nerve Radiofrequency Ablation and Steroid Injection: Combination Therapy for Coccydynia. J Ultrasound Med. 2023. PMID: 37706553. doi:10.1002/jum.16334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。